Cardiac Failure ReviewPub Date : 2026-11-02eCollection Date: 2026-01-01DOI: 10.15420/cfr.2026.49
Cathy West, Kristyan Guppy-Coles, James W Armstrong, Matthew Johnstone, Adam Scott, John J Atherton
{"title":"Safety and Usability of a Novel, Robotic Assistance System for Echocardiographic Examination.","authors":"Cathy West, Kristyan Guppy-Coles, James W Armstrong, Matthew Johnstone, Adam Scott, John J Atherton","doi":"10.15420/cfr.2026.49","DOIUrl":"https://doi.org/10.15420/cfr.2026.49","url":null,"abstract":"<p><strong>Background: </strong>Transthoracic echocardiography (TTE) is essential for modern cardiac diagnostics, yet it is difficult to access in remote areas. Remotely operated robotic-assisted ultrasound may enable access to services in rural and remote locations, while also improving ergonomics for the sonographer. This study evaluated the safety, usability and patient satisfaction of a novel robotic ultrasound assistance tool (RUAT).</p><p><strong>Methods: </strong>This open-label, single-site, single-arm clinical trial enrolled adult participants who had recently completed a standard manual echocardiogram. A trained sonographer performed a robot-assisted TTE from a dedicated workstation in the same room as the patient. Endpoints included safety measured by adverse events, technical and clinical usability, and patient satisfaction using surveys about the participants' experience.</p><p><strong>Results: </strong>The trial cohort (n=30; mean age 62.9 ± 17.5 years; 70% men) all successfully completed the robot-assisted TTE and the patient satisfaction survey. There were no adverse events or adverse device effects. The functional verification checklist supporting technical usability demonstrated an average usability rate of 96.9% (95% CI [98.9-100.0]), with a 100% rate across 10 of 12 metrics. The sonographer's review of the acquired robotic images measured the clinical usability and 29 of 30 examinations met acceptable diagnostic standards (96.7%; 95% CI [88.1-100.0]). The mean participant satisfaction score was 8.3 out of 10, with 96.7% scoring ≥6.</p><p><strong>Conclusion: </strong>The RUAT demonstrated high technical and clinical usability, as well as high acceptance by participants. These findings indicate that robot-assisted TTE is a viable strategy to enhance remote access to TTE services.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e36"},"PeriodicalIF":12.2,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-10-29eCollection Date: 2026-01-01DOI: 10.15420/cfr.2026.14
Andrew J Stewart Coats, Giuseppe Rosano
{"title":"Foreword: Sleep-disordered Breathing in Heart Failure.","authors":"Andrew J Stewart Coats, Giuseppe Rosano","doi":"10.15420/cfr.2026.14","DOIUrl":"10.15420/cfr.2026.14","url":null,"abstract":"","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e34"},"PeriodicalIF":12.2,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13749407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-10-29eCollection Date: 2026-01-01DOI: 10.15420/cfr.2026.53
Ovidiu Chioncel, Javed Butler, Andrew Js Coats, Gad Cotter
{"title":"Acute Heart Failure: Looking into the Past to Understand the Future.","authors":"Ovidiu Chioncel, Javed Butler, Andrew Js Coats, Gad Cotter","doi":"10.15420/cfr.2026.53","DOIUrl":"10.15420/cfr.2026.53","url":null,"abstract":"","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e35"},"PeriodicalIF":12.2,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13749414/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-09-30eCollection Date: 2026-01-01DOI: 10.15420/cfr.2026.22
Aurora Merolla, Patrizia Rovere-Querini
{"title":"Glucagon-like Peptide-1-based and Emerging Cardiometabolic Therapies in Heart Failure with Preserved Ejection Fraction: Linking Molecular Mechanisms to Clinical Outcomes.","authors":"Aurora Merolla, Patrizia Rovere-Querini","doi":"10.15420/cfr.2026.22","DOIUrl":"10.15420/cfr.2026.22","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical syndrome driven by frequent coexistence of cardio-renal-metabolic comorbidities. It has growing epidemiological relevance as global populations age. At its pathophysiological core lies a state of chronic systemic inflammation, coronary microvascular dysfunction and myocardial remodelling, a cascade where epicardial adipose tissue plays a pivotal amplifying role. This complexity is driving a fundamental shift in HFpEF management towards integrated cardiometabolic targeting. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual GLP1/glucose-dependent insulinotropic polypeptide (GIP)-RA tirzepatide have emerged as compelling multi-system agents, simultaneously addressing several key pathophysiological drivers of the syndrome with consistent improvements in symptoms, functional capacity and clinical outcomes. Nevertheless, questions remain regarding the long-term impact on cardiovascular outcomes, consequences of discontinuing treatment and the potential loss of muscle mass. This review examines the pathophysiological basis of HFpEF within the cardio-renal-metabolic continuum, appraising the clinical evidence, benefits and limitations of GLP-1RAs in HFpEF and discussing future directions including phenotype-directed therapy, mechanism-based combination strategies and next-generation molecules.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e33"},"PeriodicalIF":12.2,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-09-30eCollection Date: 2026-01-01DOI: 10.15420/cfr.2026.10
Sudesh Prajapathi, Akshyaya Pradhan, Kunal Mahajan, Rajeev Agarwala, Marco Alfonso Perrone
{"title":"Overcoming Hyperkalaemia to Optimise Heart Failure Therapy: The Emerging Role of Novel Potassium Binders.","authors":"Sudesh Prajapathi, Akshyaya Pradhan, Kunal Mahajan, Rajeev Agarwala, Marco Alfonso Perrone","doi":"10.15420/cfr.2026.10","DOIUrl":"https://doi.org/10.15420/cfr.2026.10","url":null,"abstract":"<p><p>Hyperkalaemia is common in patients with heart failure. It limits the initiation, optimisation and continuation of guideline-directed medical therapy, particularly mineralocorticoid receptor antagonists. Two potassium binders, patiromer and sodium zirconium cyclosilicate (SZC), have emerged as strategies to address this barrier. SZC is an inorganic crystalline compound that binds potassium in exchange for sodium and hydrogen throughout the gastrointestinal tract, resulting in rapid potassium lowering, whereas patiromer is a non-absorbed organic polymer that exchanges potassium for calcium in the colon and has a slower onset of action. Both agents have demonstrated efficacy in maintaining normokalaemia and enabling the continuation of renin-angiotensin-aldosterone system inhibitor therapy in heart failure. Differences in electrolyte effects and tolerability have clinical implications: patiromer is associated with hypomagnesaemia, while SZC delivers a sodium load that may predispose patients to fluid retention. However, no head-to-head randomised trials are available and evidence for improvement in heart failure morbidity or mortality remains limited, underscoring the need for adequately powered outcome studies.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e32"},"PeriodicalIF":12.2,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-09-23eCollection Date: 2026-01-01DOI: 10.15420/cfr.2025.40
Agustín Fernández-Cisnal, Anna Mollar, Gema Miñana, Rafael de la Espriella, Enrique Santas, Miguel Lorenzo, César Romero Menor, Julio Núñez
{"title":"The Expanding Role of Carbohydrate Antigen 125 in Heart Failure: From Tumour Marker to a Cornerstone of Heart Failure Management. An Updated Narrative Review.","authors":"Agustín Fernández-Cisnal, Anna Mollar, Gema Miñana, Rafael de la Espriella, Enrique Santas, Miguel Lorenzo, César Romero Menor, Julio Núñez","doi":"10.15420/cfr.2025.40","DOIUrl":"10.15420/cfr.2025.40","url":null,"abstract":"<p><p>Congestion is central to heart failure (HF) but remains difficult to quantify. Carbohydrate antigen 125 (CA125), also known as mucin 16, released by mesothelial cells, captures two pathways relevant to HF: fluid overload and inflammation. This narrative review summarises biological mechanisms and clinical applications. Across acute and chronic settings, CA125 tracks systemic and right-sided congestion, complements natriuretic peptides and shows lower dependence on renal function. Higher levels identify patients at risk for death and readmission; in ambulatory HF with reduced ejection fraction it predicts events, while in HF with preserved ejection fraction its signal is strongest in congestion-dominant phenotypes. Serial testing mirrors decongestion and clinical course; CA125-guided care has reduced rehospitalisations and improved renal function measures in selected populations. Advantages, wide availability, standardisation and low cost, support use in practice. Key gaps include phenotype-specific threshold, sampling interval and integration into actionable algorithms. Overall, CA125 has moved from tumour marker to practical tool that refines congestion assessment, improves risk stratification and informs individualised therapy in contemporary HF care.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e31"},"PeriodicalIF":12.2,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13655751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149172155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-09-10eCollection Date: 2026-01-01DOI: 10.15420/cfr.2026.44
Maria Giulia Bellicini
{"title":"Valvular Heart Disease as the Main Cause of Acute Heart Failure with Preserved Ejection Fraction: Dynamic Severe Functional Valvular Regurgitation as the Main Mechanism of Decompensation.","authors":"Maria Giulia Bellicini","doi":"10.15420/cfr.2026.44","DOIUrl":"10.15420/cfr.2026.44","url":null,"abstract":"","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e28"},"PeriodicalIF":12.2,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-09-10eCollection Date: 2026-01-01DOI: 10.15420/cfr.2025.62
Ren Ping Liu, Lauren E Watson, Julie R McMullen
{"title":"Understanding Exercise-induced Protection in Heart Failure with Reduced Ejection Fraction and Heart Failure with Preserved Ejection Fraction: Molecular Mechanisms and New Therapeutic Opportunities.","authors":"Ren Ping Liu, Lauren E Watson, Julie R McMullen","doi":"10.15420/cfr.2025.62","DOIUrl":"10.15420/cfr.2025.62","url":null,"abstract":"<p><p>Heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) are subtypes of heart failure with overlapping clinical features but have some distinct functional characteristics and cellular and molecular mechanisms. Exercise training is an accessible, non-pharmacological therapy recommended for the management of HFrEF and is increasingly showing promise for treating HFpEF. This review summarises the underlying pathophysiology of HFrEF and HFpEF and the evidence from clinical and preclinical studies showing that exercise training can improve cardiac function. The authors also summarise the underlying cellular and molecular mechanisms between HFrEF and HFpEF, with respect to cardiac remodelling, fibrosis, mitochondrial adaptations and metabolism, inflammation and inter-organ crosstalk, and provide evidence that exercise training elicits protective adaptations in HFrEF and HFpEF through some different signalling pathways targeted by exercise. Finally, the authors discuss the use of exercise training as a therapeutic intervention for HFrEF and HFpEF through personalised training by phenotype and in combination with emerging pharmacological treatments.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e30"},"PeriodicalIF":12.2,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-09-10eCollection Date: 2026-01-01DOI: 10.15420/cfr.2025.24
Jorge Mora, Bernie Sunwoo, Matheus Ramsis, Atul Malhotra
{"title":"Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea.","authors":"Jorge Mora, Bernie Sunwoo, Matheus Ramsis, Atul Malhotra","doi":"10.15420/cfr.2025.24","DOIUrl":"10.15420/cfr.2025.24","url":null,"abstract":"<p><p>Obstructive sleep apnoea and central sleep apnoea are common disorders, particularly in people with congestive heart failure. Continuous positive airway pressure provides transformative benefits for some patients, but is not always well tolerated. Thus, considerable focus is now being placed on alternative therapies for sleep-disordered breathing, including non-positive airway pressure therapy. Advances in pharmacology have led to a variety of options to treat both obstructive and central sleep apnoea. In addition, these approaches may have major benefits from the perspective of preventing the complications of sleep-disordered breathing. In the case of tirzepatide, the Food and Drug Administration recently approved this medication for the treatment of moderate-to-severe sleep apnoea in people with obesity. However, further data are required regarding how best to improve both subjective and objective hard outcomes in people with congestive heart failure and sleep-disordered breathing.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e29"},"PeriodicalIF":12.2,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiac Failure ReviewPub Date : 2026-09-08eCollection Date: 2026-01-01DOI: 10.15420/cfr.2026.25
James Smith, David Wilson, Amy Rose Stewart, Trung Nguyen, Justin Beilby, Lisa Collison, Lynda Whiteway, Rachel Ambagtsheer, Rebecca Perry, David Playford, Yih-Kai Chan, Simon Stewart
{"title":"Finding and Managing Heart Failure Earlier: Why Enhancing Primary Care Teams to Apply More Definitive Surveillance is the Solution.","authors":"James Smith, David Wilson, Amy Rose Stewart, Trung Nguyen, Justin Beilby, Lisa Collison, Lynda Whiteway, Rachel Ambagtsheer, Rebecca Perry, David Playford, Yih-Kai Chan, Simon Stewart","doi":"10.15420/cfr.2026.25","DOIUrl":"10.15420/cfr.2026.25","url":null,"abstract":"<p><p>Typically, heart failure (HF) is definitively diagnosed and treated with guideline-directed medical therapy late in its natural history, with reported delays, missed investigation and inpatient diagnoses associated with poor outcomes. Accordingly, better, more decisive primary care can and should play a critical role in addressing this seemingly intractable problem. However, as reflected by a paucity of evidence to inform the recommendations of expert HF guidelines, primary care teams are rarely considered as part of the solution. In this review, we explore all the potential outcomes from more proactive screening for HF in primary care when introducing artificial intelligence-mediated portable cardiac ultrasound. Based on the strengths and weaknesses of the screening components that can now be applied, we consider the spectrum of early to late forms of HF likely to be revealed and more immediately diagnosed. Within this context, we present, as an example of what can be achieved in this space, a clinical algorithm that was developed for a prospective, multicentre project to find and manage HF earlier in the primary care setting.</p>","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"12 ","pages":"e27"},"PeriodicalIF":12.2,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13595251/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}